

[A004]



Faculty of Education

Department of Chemistry

Lab of Organic Synthesis

Substituted Pyridopyrimidinones. 1.

Convenient PTC Alkylation and Halogenation of
2-Hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one

Mohamed Abass* and Aisha S. Mayas

Department of Chemistry, Faculty of Education, Ain Shams University,
Roxy, Cairo 11757, Egypt. e-mail: quinolinone@yahoo.com

Abstract: Alkylation of 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (1) was investigated under solid-liquid phase transfer catalysis conditions (PTC), using tetrabutylammonium bromide and potassium carbonate. The reaction with alkyl halides led to the formation of various 2-alkoxy products, in fair yields. Reaction of compound 1 with epichlorohydrin and chloroacetonitrile, under the same PTC conditions, afforded novel O1,O3-disubstituted glycerol and oxazolo-pyridopyrimidone betain derivatives, respectively. Some 3-halo-, 3,3-dihalo and/or 2,3-dihalopyrido[1,2-a]pyrimidines were also prepared using different halogenating agents at different reaction conditions.


INTRODUCTION

Over the last eighty years and from the time when Tschitschibabin had prepared 2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one and characterized as pyrido[1,2-a]-pyrimidine-2,4-dione, under the name of malonyl- α -aminopyridine [1], many synthetic and reaction studies had been carried out dealing with its derivatives. The distinguished and unique chemical properties [2-5] and biological applications of 4H-pyrido[1,2-a]pyrimidin-4-one

derivatives [6-10] evoked an importance for the continuation of the synthetic and chemical researches in this field. Herein, We are willing to obtain new derivatives of pyrido[1,2-*a*]pyrimidin-4-one via alkylation under phase transfer catalysis conditions and also study halogenation reaction of the titled compound in order to obtain new optionally functionalized pyrido[1,2-*a*]pyrimidin-4-ones of synthetic importance.

RESULTS AND DISCUSSION

It is reported that 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**1**) is smoothly prepared *via* thermal condensation of 2-aminopyridine with diethyl malonate [1, 2, 11, 12]. According to this methodology we separated two different malonyl heterocycles *via* differential crystallization. The major product was characterized as the pyridopyrimidinone **1** and the minor product as 4-hydroxy-1,8-naphthyridin-2(1*H*)-one (**2**) [13].



SCHEME 1.

Carrying out the reaction at gentle heating at 100–110 °C for *ca.* six hours minimized the amount of naphthyridinone by-product, while elevated temperatures (*ca.* 180-200 °C) increased the amount of naphthyridinone **2**, reaching 40 % of the converted 2-aminopyridine. The formation of naphthyridinone **2** can be attributed to the reported thermal rearrangement of the pyridopyrimidin-4-ones *via* carbonyl ketene intermediate [14] (Scheme 1).

Etherification is one of the most common PTC reactions and is applicable to a wide variety of alcohols and phenols. The advantage of PTC is back to its effectiveness, easiness, higher yield, shorter time, inexpensive inorganic base and environment-friendly green methodology [15, 16]. Reaction of compound **1** with alkyl halides namely; methyl iodide, ethyl iodide, propyl bromide, and allyl bromide, was carried out under PTC-conditions using K_2CO_3 , tetrabutylammonium bromide (TBAB), in acetone. Figure 1 shows a mechanistic pathway for the alkylation of compound **1**, which may proceed via an S_N2 -mechanism.






FIGURE 1. PTC alkylation of 2-hydroxypyrido[1,2-*a*]pyrimidin-4(1H)-one.

The corresponding 2-alkoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones **3a-d** were obtained in 58-86 %. However, ¹H NMR of the product **3d** revealed the specific set of signals due to the allyloxy grouping as doublet at d 4.87 due to (OCH₂CH=CH₂) and the signal of proton at position-3 appeared very near at d = 4.94 ppm, as singlet. This confirmed that *O*-alkylation took place and the formation of either 3-alkylated derivative **4** or *N*-alkylated derivative **5** should be excluded under the present conditions (Scheme 2).

Similarly, alkyl haloacetates, *viz.* methyl chloroacetate and ethyl bromoacetate, were reacted with compound **1** to obtain the corresponding alkyl [(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]acetates (**3e,f**). The chemical shifts, at d 5.02 ppm for **3e** (R = CO₂CH₃), and at d 4.99 ppm for **3f** (R = CO₂C₂H₅), indicated that *O*-alkylation selectivity took place. Ethyl (4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)carbonate (**6**) was obtained, in 71 % yield, when compound **1** was allowed to react with ethyl chloroformate under the same PTC conditions. Treatment of the compound **1** with *N*-(2-bromoethyl)phthalimide (**7**) using PTC-conditions furnished 2-{2-[(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]ethyl}-isoindole-1,3-(2*H*)-dione (**8**) (Scheme 2). IR spectrum of compound **8** revealed additional (C=O) stretching vibrations at ν 1713 and 1692 cm⁻¹ characteristic for phthalimide moiety [17], while ¹H NMR spectrum showed two triplet sets of signals at d 3.73 and 4.01 specific for (NCH₂-CH₂O).




2-[(Oxiran-2-yl)methoxy]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**9**) was obtained *via* treatment of compound **1** with epichlorohydrin under PTC-conditions [18]. Triethylamine catalyzed-addition of compound **1** to the oxiran **9** afforded 2-{2-hydroxy-3-[(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]propoxy}-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**10**). Due to the reported potential antihypertensive activity of naphthyridinone oxime ethers obtained by addition of alkyl amines to its oxiranylmethyl precursors [19], the compound **9** was subjected to react with isopropylamine and *tert*-butylamine. The addition took place in good yields in the presence of potassium carbonate and cetyltrimethylammonium bromide (CTAB), affording the corresponding 2-(3-alkylamino-2-hydroxypropoxy)pyridopyrimidinones **11a,b** (R = H, R = CH₃) (Scheme 3).



Under the same PTC-conditions, chloroacetonitrile was reacted with compound **1** in order to give [(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]acetonitrile (**12**). Unexpectedly IR spectrum


did not show the absorption band characteristic for (C≡N). ¹H NMR showed that pyrimidinone β-proton is more downfield shifted (d 5.83) than its ordinary position (d ≈ 5.0). Also the deuterium non-exchangeable two protons, which appeared as singlet peak at d 4.81, interpreted as methylenic protons excluding formation of aminofuopyridopyrimidinone **13**. Anyhow, these results can be explained if we assumed that the product exhibited the stable mesoionic form (5-oxo-5*H*-oxazolo[3,2-*c*]pyrido[1,2-*a*]pyrimidin-11-ium-1(2*H*)-ylidene)azanide (**14**) (Scheme 4).



SCHEME 4

Chlorination of pyridopyrimidinone **1** with phosphoryl chloride was found temperature dependent. Thus, heating of the compound **1** with phosphoryl chloride, at 100-105 °C, furnished only 2-chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**15**) [2, 20]. Interestingly the same compound was obtained in higher yield (88 %) on using oxalyl chloride instead of phosphoryl chloride [21]. Under drastic thermal conditions (200–220 °C) a mixture of phosphoryl chloride and phosphorus pentachloride led to the formation of 2,3-dichloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**16**) (Scheme 5).

It is well known that sulfuryl chloride is a suitable reagent for *C*-chlorination of fused γ -hydroxy- α -pyridone derivatives [5, 13, 22]. Thus, the reaction of compound **1** with sulfuryl chloride led to only 3-chloro-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**17**), in 67 % yield. Analytical and spectral data showed no evidence for the formation of the expected product 3,3-dichloro-2*H*-pyrido[1,2-*a*]pyrimidine-2,4(3*H*)-dione (**18**). Nevertheless, the compound **17** was obtained earlier, as by-product during chlorination of compound **1** [2]. Conversion of compound **17** into the 2,3-dichloro derivative **16** was affected by action of phosphorus oxychloride. Conversely acid hydrolysis of compound **16** led to the 3-chloro-2-hydroxy derivative **17** (Scheme 5).



SCHEME 5

3-Bromo-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**19**) was prepared by reaction of compound **1** with bromine in acetic acid at room temperature [23]. Treating compound **1** with excess bromine in dioxane led to the formation of 3,3-dibromo-2*H*-pyrido[1,2-*a*]pyrimidin-2,4(3*H*)-one (**20**). IR spectrum represented two characteristic absorption vibrations at ν 1720 and 1690 cm^{-1} corresponding to 2,4-dioxo groups. ^1H NMR spectrum showed four sets of peaks at δ 7.49, 7.75, 8.08, and 9.03 due to 1,2-disubstituted pyridine protons. Moreover, the mono-bromo derivative **19** was smoothly converted into the dibromo derivative **20** on treating with excess bromine in dioxane.

Finally, the compound **1** was selectively iodinated using iodine in dioxane to give 2-hydroxy-3-iodo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**21**) in 77% yield (Scheme 5).

CONCLUSION

In general, it is remarked that alkylation under the PTC conditions neither C3- nor N1-alkylation took place, while the reaction selectivity took place at the hydroxy group leading to O-alkylation derivatives. Halogenation with replacement of one or two protons at position 3 of 2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one was observed on treating with sulfonyl chloride, bromine and iodine in the proper solvents. Chlorination with phosphoryl chloride and/or phosphorus pentachloride led to formation of the 2-chloro and 2,3-dichloro derivatives. Oxalyl chloride is suitable for replacement of hydroxyl group at position 2 affording only the 2-chloro derivative.

EXPERIMENTAL

Melting points are uncorrected and were determined in open capillary tubes on a digital Gallen-Kamp MFB-595. IR spectra were taken on a Perkin-Elmer FT-IR 1650, using samples in KBr disks. ^1H NMR spectra were recorded on Varian Gemini-200 spectrometer (200 MHz) MHz, using $\text{DMSO-}d_6$ or CDCl_3 as solvents and TMS as internal reference. Mass spectra were determined on a Shimadzu GC-MS-QP 1000 EX instrument or HP-MS 5988 mass spectrometer by direct inlet, operating at 70 eV. Elemental microanalyses were performed on a Perkin-Elmer CHN-2400 Analyzer.

2-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**1**) and 4-Hydroxy-1,8-naphthydrin-2(1*H*)-one (**2**)

A mixture of 2-aminopyridine (0.1 mol) and freshly distilled dry diethyl malonate (0.12 mol) was heated at 100–110 °C till complete precipitation for about 6 h. The mixture was then cooled, triturated with diethyl ether (100 mL), washed several times with diethyl ether to remove unreacted materials, and crystallized from water to give the compound **1**, m.p. 296–298 °C, (Lit. m.p. 295–298 °C [11]; 305–308 °C [12]). This first crop was crystallized from DMF without significant change in the melting point (297–299 °C). The mother-liquor of water crystallization was concentrated to one third of its initial volume and left to stand at room temperature over night to give compound **2**. Then the obtained sandy crystalline material was collected by filtration, m.p. 292–294 °C, (Lit. m.p. 292–294 °C [13]).

PTC-Alkylation of Compound **1**: Preparation of Ethers **3a-f**, **6**, **8**, **9** and Compound **14**

General Method: To a mixture of the compound **1** (1.62 g, 10 mmol), potassium carbonate (2.79 g, 20 mmol) and TBAB (0.3 g), in dry acetone (50 mL), the proper alkylating agent (11 mmol), namely; methyl iodide (0.7 mL), ethyl iodide (0.9 mL), propyl bromide (1 mL), allyl bromide (1 mL), methyl chloroacetate (1 mL), ethyl bromoacetate (1.3 mL), ethyl chloroformate (1.1 mL), 2-(2-bromoethyl)isoindole-1,3(2*H*)-dione (**7**) (2.97 g), epichlorohydrin (0.9 mL), and chloroacetonitrile (0.7 mL), was added. Then the mixture was heated under reflux on a water-bath for 4–8 h and filtered off while hot. The solvent was evaporated in vacuum and the solid residue was crystallized from the proper solvent to give the title compounds. The filtration solid residue was dissolved in cold water (25 mL) and extracted with chloroform (3 X 25 mL). The combined extracts were dried over anhydrous sodium sulfate (10 g), filtered off and evaporated to recover unreacted material **1**.

2-Methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**3a**), mp 145–147 °C (methanol); yield 1.52 g (86%), Lit. [20] mp 146–148 °C (41%).

2-Ethoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**3b**), mp 114–116 °C (ethanol); yield 1.51 g (79%). IR (KBr), $\nu_{\text{max}}/\text{cm}^{-1}$ 1711 (C=O), 1634 (C=N), 1575, 1536; ^1H NMR (CDCl_3), δ 1.26 (t, 3H, OCH_2CH_3), 4.04 (q, 2H, OCH_2CH_3), 5.58 (s, 1H, 3-H), 7.32 (t, 1H, 7-H), 7.52 (d, 1H, 9-H), 7.78 (t, 1H, 8-H), 8.99 (d, 1H, 6-H). Anal calcd for $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_2$ (190.20): C, 63.15; H, 5.30; N, 14.73. Found: C, 62.90; H, 5.22; N, 14.56%.

2-Propoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**3c**), mp 88–90 °C (ethanol); yield 1.49 g (73%), Lit. [3] mp 87–92 °C (9.5%).

2-Allyloxy-4H-pyrido[1,2-*a*]pyrimidin-4-one (3d), mp 203-205 °C (ethanol); yield 1.17 g (58%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1700 (C=O), 1648 (C=N), 1620 (C=C), 1557, 1508; ^1H NMR (DMSO- d_6), δ 4.87 (d, 2H, OCH₂CH=CH₂), 4.94 (s, 1H, 3-H), 5.04–5.19 (d, 2H, OCH₂CH=CH₂), 5.90 (m, 1H, OCH₂CH=CH₂), 7.44 (t, 1H, 7-H), 7.67 (d, 1H, 9-H), 8.29 (t, 1H, 8-H), 9.17 (d, 1H, 6-H). Anal calcd for C₁₁H₁₀N₂O₂ (202.21): C, 65.34; H, 4.98; N, 13.85. Found: C, 65.25; H, 4.86; N, 13.77%.

Methyl [(4-oxo-4H-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]acetate (3e), mp 128-129 °C (methanol); yield 1.47 g (63%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1765 (C=O), 1693 (C=O), 1634 (C=N), 1573, 1530; ^1H NMR (DMSO- d_6), δ 3.70 (s, 3H, OCH₃), 5.02 (s, 2H, OCH₂CO), 5.77 (s, 1H, 3-H), 7.38 (t, 1H, 7-H), 7.55 (d, 1H, 9-H), 8.03 (t, 1H, 8-H), 8.98 (d, 1H, 6-H). Anal calcd for C₁₁H₁₀N₂O₄ (234.21): C, 56.41; H, 4.30; N, 11.96. Found: C, 56.40; H, 4.52; N, 11.62%.

Ethyl [(4-oxo-4H-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]acetate (3f), mp 106-107 °C (acetone); yield 2.18 g (88%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1748 (C=O), 1691 (C=O), 1636 (C=N), 1572, 1527; ^1H NMR (DMSO- d_6), δ 1.21 (t, 3H, OCH₂CH₃), 4.17 (q, 2H, OCH₂CH₃), 4.99 (s, 2H, OCH₂CO), 5.77 (s, 1H, 3-H), 7.41 (t, 1H, 7-H), 7.54 (d, 1H, 9-H), 8.01 (t, 1H, 8-H), 8.98 (d, 1H, 6-H); MS, m/z (*I*%) 249 (11) [M+1]⁺, 248 (80) M⁺, 220 (21), 203 (19), 175 (54), 148 (16), 145 (40), 134 (34), 118 (29), 79 (13), 78 (100). Anal calcd for C₁₂H₁₂N₂O₄ (248.24): C, 58.06; H, 4.87; N, 11.28. Found: C, 58.08; H, 5.24; N, 11.10%.

Ethyl (4-oxo-4H-pyrido[1,2-*a*]pyrimidin-2-yl)carbonate (6), mp 102-104 °C (ethanol); yield 1.66 g (71%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1748 (C=O), 1691 (C=O), 1636 (C=N), 1572, 1527; ^1H NMR (DMSO- d_6), δ 1.32 (t, 3H, OCH₂CH₃), 4.31 (q, 2H, OCH₂CH₃), 6.28 (s, 1H, 3-H), 7.48 (t, 1H, 7-H), 7.72 (d, 1H, 9-H), 8.10 (t, 1H, 8-H), 9.02 (d, 1H, 6-H). Anal calcd for C₁₁H₁₀N₂O₄ (234.21): C, 56.41; H, 4.30; N, 11.96. Found: C, 56.50; H, 4.22; N, 11.75%.

2-{2-[(4-Oxo-4H-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]ethyl}isoindole-1,3(2H)-dione (8), mp 183-185 °C (acetic acid); yield 2.28 g (68%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1713 (C=O), 1690 (C=O), 1620 (C=N), 1600, 1572, 1529; ^1H NMR (DMSO- d_6), δ 3.73 (t, 2H, NCH₂CH₂O), 4.01 (t, 2H, NCH₂CH₂O), 5.60 (s, 1H, 3-H), 7.35 (t, 1H, 7-H), 7.64 (d, 1H, 9-H), 7.80-7.89 (m, 5H, H_{arom} + 8-H), 8.86 (d, 1H, 6-H). Anal calcd for C₁₈H₁₃N₃O₄ (335.32): C, 64.48; H, 3.91; N, 12.53. Found: C, 64.21; H, 3.74; N, 12.46%.

2-[(Oxiran-2-yl)methoxy]-4H-pyrido[1,2-*a*]pyrimidin-4-one (9), mp 150-152 °C (ethanol); yield 1.35 g (62%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1700 (C=O), 1633 (C=N), 1600, 1572, 1527; ^1H NMR (DMSO- d_6), δ 3.42 (m, 1H, CH_{oxiran}), 3.47 (d, 2H, CH_{2oxiran}), 4.42 (d, 2H, OCH₂), 5.67 (s, 1H, 3-H), 7.28 (t, 1H, 7-H), 7.51 (d, 1H, 9-H), 7.96 (t, 1H, 8-H), 8.90 (d, 1H, 6-H). Anal calcd for C₁₁H₁₀N₂O₃ (218.21): C, 60.55; H, 4.62; N, 12.84. Found: C, 60.39; H, 4.55; N, 12.82%.

(5-Oxo-5H-oxazolo[3,2-*c*]pyrido[1,2-*a*]pyrimidin-11-ium-1(2H)-ylidene)azanide (14), mp 157-159 °C (acetone); yield 1.13 g (56%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1707 (C=O), 1640 (C=N), 1578, 1531; ^1H NMR (DMSO- d_6), δ 4.81 (s, 2H, 2-CH₂), 5.83 (s, 1H, 4-H), 7.32 (t, 1H, 8-H), 7.82 (d, 1H, 10-H), 7.94 (t, 1H, 9-H), 9.08 (d, 1H, 7-H); MS, m/z (*I*%) 202 (12) [M+1]⁺, 201 (100) M⁺, 173 (30), 146 (14), 133 (64), 118 (34), 105 (58), 78 (96), 69 (42). Anal calcd for C₁₀H₇N₃O₂

(201.19): C, 59.70; H, 3.51; N, 20.89. Found: C, 59.60; H, 3.78; N, 20.73%.

2-{2-Hydroxy-3-[(4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)oxy]propoxy}-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**10**)

Equimolar amounts (5 mmol) of the oxiran derivative **9** (1.09 g) and compound **1** (0.81 g), in absolute ethanol (15 mL) were treated with triethylamine (0.1 mL) and the mixture was gently warmed at 60 °C for 2 h. The precipitate that formed was then filtered off and crystallized from ethanol (95%) to give compound **10**, mp 218-220 °C; yield 1.01 g (53%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1700 (C=O), 1685 (C=O), 1635 (C=N), 1570, 1530, 1459; $^1\text{H NMR}$ (DMSO-*d*₆), δ 3.45 (s, 1H, OH), 4.19 (m, 1H, CHOH), 4.35 (d, 4H, (OCH₂)₂CHOH), 5.68 (s, 2H, 3-H), 7.31 (t, 2H, 7-H), 7.53 (d, 2H, 9-H), 7.97 (t, 2H, 8-H), 8.92 (d, 2H, 6-H). Anal calcd for C₁₉H₁₆N₄O₅ (380.36): C, 60.00; H, 4.24; N, 14.73. Found: C, 59.88; H, 4.21; N, 14.56%.

Addition of Alkylamines to Oxirane **9**: Preparation of Propanolamines **11a,b**

General Method: A solution of the suitable alkylamine (5 mmol), namely; *iso*-propylamine (0.5 mL), *tert*-butylamine (0.6 mL) in dioxane (10 mL) was added to a mixture of oxirane **9** (1.09 g, 5 mmol), dry potassium carbonate (1.39 g, 10 mmol) and CTAB (0.5 g) in dioxane (25 mL). Then the mixture was stirred at room temperature for 24h. The organic solution was evaporated to dryness in vacuum and the crude residue was treated with water and extracted with chloroform. The combined extracts were dried over anhydrous sodium sulfate, filtered off and the filtrate was evaporated in vacuum. The residue was crystallized from the proper solvent to give the propanolamines **11a,b**.

2-[2-Hydroxy-3-(isopropylamino)propoxy]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**11a**), mp 101-102 °C (methanol); yield 1.14 g (82%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 3426 (N-H), 1690 (C=O), 1624 (C=N), 1587, 1512; $^1\text{H NMR}$ (CDCl₃), δ 1.18 (d, 6H, NCH(CH₃)₂), 2.61 (m, 1H, NCH(CH₃)₂), 2.93 (d, 2H, NCH₂CHOH), 3.86 (m, 1H, (CH₂)₂CHOH), 4.11 (d, 2H, OCH₂CHOH), 4.48 (d, 1H, OH), 5.88 (s, 1H, 3-H), 7.26 (t, 1H, 7-H), 7.49 (d, 1H, 9-H), 7.71 (t, 1H, 8-H), 9.01 (d, 1H, 6-H). Anal calcd for C₁₄H₁₉N₃O₃ (277.33): C, 60.63; H, 5.91; N, 15.15. Found: C, 60.45; H, 5.86; N, 14.97%.

2-[2-Hydroxy-3-(*tert*-butylamino)propoxy]-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**11b**), mp 87-89 °C (petroleum ether (60-80 °C)); yield 1.08 g (74%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 4422 (N-H), 1689 (C=O), 1618 (C=N), 1578, 1522; $^1\text{H NMR}$ (CDCl₃), δ 1.12 (s, 9H, NC(CH₃)₃), 2.91 (d, 2H, NCH₂CHOH), 3.88 (m, 1H, (CH₂)₂CHOH), 4.18 (d, 2H, OCH₂CHOH), 4.45 (d, 1H, OH), 5.83 (s, 1H, 3-H), 7.31 (t, 1H, 7-H), 7.54 (d, 1H, 9-H), 7.76 (t, 1H, 8-H), 8.95 (d, 1H, 6-H). Anal calcd for C₁₅H₂₁N₃O₃ (291.35): C, 61.84; H, 7.27; N, 14.42. Found: C, 61.60; H, 7.26; N, 14.27%.

2-Chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**15**)

A mixture of compound **1** (1.62 g, 10 mmol) and oxalyl chloride (2.7 mL, 30 mmol) was heated on boiling-water bath under reflux for 1h. Then the reaction mixture was left to cool and

quenched with crushed ice. The precipitate so formed was then filtered off and crystallized from water to give the chloro derivative **15**, mp 156-158 °C; yield 1.59 g (88%). An authentic sample was prepared using phosphoryl chloride, mp 156-158 °C; yield 0.8 g (44%), according to Lit [2]. IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1709 (C=O), 1638 (C=N), 1568, 1524, 1480, 845, 776; ^1H NMR (DMSO- d_6), δ 6.48 (s, 1H, 3-H), 7.49 (t, 1H, 7-H), 7.72 (d, 1H, 9-H), 8.12 (t, 1H, 8-H), 8.98 (d, 1H, 6-H). Anal calcd for $\text{C}_8\text{H}_5\text{ClN}_2\text{O}$ (180.59): C, 53.21; H, 2.79; Cl, 19.63; N, 15.51. Found: C, 53.20; H, 2.66; Cl, 19.50; N, 15.32%.

2,3-Dichloro-4H-pyrido[1,2-a]pyrimidin-4-one (**16**)

To a mixture of phosphorus pentachloride (5.3 g, 25 mmol) and phosphoryl chloride (4.7 mL, 50 mmol), was added 10 mmol of either compounds **1** (1.62 g) or **17** (1.96 g) and the mixture was heated on a mantle at 200-220 °C for 0.5h. Then the reaction mixture was left to cool and poured onto crushed ice to give a suspension. Complete precipitation was achieved by treating the aqueous suspension with sodium hydroxide (8%) till neutralization. The precipitate so formed was then filtered off and crystallized from acetone to give the dichloro derivative **16**, mp 222-224 °C; yield 1.14 g (53%), Lit [2] mp 225.8-226.5 °C. IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1696 (C=O), 1630 (C=N), 1555, 1514, 1465, 823, 777; ^1H NMR (DMSO- d_6), δ 7.53 (t, 1H, 7-H), 7.76 (d, 1H, 9-H), 8.22 (t, 1H, 8-H), 9.02 (d, 1H, 6-H). Anal calcd for $\text{C}_8\text{H}_4\text{Cl}_2\text{N}_2\text{O}$ (215.04): C, 44.68; H, 1.87; Cl, 32.97; N, 13.03. Found: C, 44.43; H, 1.58; Cl, 32.80; N, 12.82%.

3-Chloro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (**17**)

Method A. To a stirred warm (60 °C) suspension of compound **1** (1.62 g, 10 mmol) in dry dioxane (20 mL), sulfuryl chloride (2 mL, 25 mmol) in dry dioxane (10 mL) was added dropwise over a period of 15 min. Then the reaction mixture was heated under reflux for 30 min, left to cool and poured onto crushed ice, and the yellow precipitate so formed was collected at a suction pump and crystallized to give compound **17**, mp 288-290 °C; yield 1.32 g (67%), Lit [2] mp 290 °C. IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 2641 (H-bonded OH), 1700 (C=O), 1625 (C=N), 1584, 1527, 1480; ^1H NMR (DMSO- d_6), δ 7.42 (t, 1H, 7-H), 7.47 (d, 1H, 9-H), 8.16 (t, 1H, 8-H), 8.96 (d, 1H, 6-H), 12.59 (b, 1H, OH). Anal calcd for $\text{C}_8\text{H}_5\text{ClN}_2\text{O}_2$ (196.59): C, 48.88; H, 2.56; Cl, 18.03; N, 14.25. Found: C, 48.79; H, 2.54; Cl, 17.90; N, 14.20%.

Method B. The 2,3-dichloro derivative **16** (1.08 g, 5 mmol) was suspended in hydrochloric acid (20 mL, 6 N) and heated under reflux for 2 h. The reaction mixture was then cooled and neutralized with sodium hydroxide. Then this aqueous solution was extracted with chloroform (3 x 20 mL). The combined organic extract was dried over anhydrous sodium sulfate (5 g), filtered off and evaporated to give a solid residue, which was crystallized to furnish the derivative **17**, identified by mp, mixed mp and spectra.

3-Bromo-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (**19**)

To a stirred solution of the compound **1** (1.62 g, 10 mmol) in glacial acetic acid (25 mL), a solution of bromine (1.6 g, 10 mmol) in glacial acetic acid (10 mL) was drop-wisely added with continuous stirring. The mixture was kept over night in an ice-bath. The crystalline product so

formed was collected by filtration and recrystallized from acetic acid to give the monobromo derivative **19**, mp 299-300 °C; yield 1.64 g (68%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 2805–2664 (H-bonded OH), 1696 (C=O), 1636 (C=N), 1557, 1542, 1473; ^1H NMR (DMSO- d_6), δ 7.45 (t, 1H, 7-H), 7.78 (d, 1H, 9-H), 8.12 (t, 1H, 8-H), 8.98 (d, 1H, 6-H), 12.05 (b, 1H, OH). Anal calcd for $\text{C}_8\text{H}_5\text{BrN}_2\text{O}_2$ (241.05): C, 39.86; H, 2.09; Br, 33.15; N, 11.62. Found: C, 39.80; H, 2.04; Br, 33.10; N, 11.49%.

3,3-Dibromopyrido[1,2-*a*]pyrimidine-2,4(3*H*)-dione (**20**)

To a stirred warm (50–60 °C) solution of 5 mmol of either the compound **1** (0.81 g) or **19** (1.2 g), in dioxane (25 mL) and water (5 mL), a solution of bromine (24 g, 15 mmol) in dioxane (10. mL) was dropped over a period of 20 min. After complete addition, the reaction mixture was heated under reflux for 30 min. The excess solvent was evaporated in vacuum and the residue was crystallized from benzene to give the dibromo derivative **20**, mp 235-238 °C; yield 1.19 g (74%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 1720 (C=O), 1690 (C=O), 1633 (C=N), 1576, 1544, 1453, 1318, 887, 776; ^1H NMR (DMSO- d_6), δ 7.49 (t, 1H, 7-H), 7.75 (d, 1H, 9-H), 8.08 (t, 1H, 8-H), 9.03 (d, 1H, 6-H). Anal calcd for $\text{C}_8\text{H}_4\text{Br}_2\text{N}_2\text{O}_2$ (319.94): C, 30.03; H, 1.26; Br, 49.95; N, 8.76. Found: C, 29.78; H, 1.20; Br, 49.70; N, 8.70%.

2-Hydroxy-3-iodo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one (**21**)

To a stirred solution of compound **1** (1.62 g, 10 mmol) and iodine (5.07 g, 20 mmol) in dry dioxane (15 mL) was added 4-methylmorpholine (1.33 ml, 12 mmol) at room temperature for 3 h. Afterwards, the solvent was evaporated in vacuum till dryness. The residue was treated with a solution of sodium hydrogen sulfite (20 mL, 1 M) and water (50 ml) was added. The mixture was extracted with chloroform (3 × 50 ml). The organic extract was washed with water, dried over sodium sulfate, and concentrated. The yellow crystals, which so precipitated was filtered and crystallized from dioxane affording the iodo derivative **21**, mp 226-228 °C; yield 1.64 g (68%). IR (KBr), $\nu_{\max}/\text{cm}^{-1}$ 2662 (H-bonded OH), 1699 (C=O), 1635 (C=N), 1602, 1571, 1545, 1473, 882, 776; ^1H NMR (DMSO- d_6), δ 7.33 (t, 1H, 7-H), 7.58 (d, 1H, 9-H), 7.79 (t, 1H, 8-H), 8.84 (d, 1H, 6-H), 11.92 (b, 1H, OH). Anal calcd for $\text{C}_8\text{H}_5\text{IN}_2\text{O}_2$ (288.05): C, 33.36; H, 1.75; I, 44.06; N, 9.73. Found: C, 33.21; H, 1.57; I, 43.80; N, 9.69%.

REFERENCES

- [1] Tschitschibabin, A. E. Ber Dtsch Chem Ges 1924, 57, 1168.
- [2] Snyder, H. R.; Robison, M. M. J Am Chem Soc 1952, 74, 4910.
- [3] Katritzky, A. R.; Waring, A. J. J Chem Soc 1962, 1544.
- [4] Schulte, W. Arch Pharm 1985, 291, 298.
- [5] Schober, B. D.; Kappe, Th. J Heterocycl Chem 1988, 25, 1231.
- [6] Ferrarini, P. L.; Mori, C.; Armani, G.; Rossi, L. Farmaco 1995, 50, 69.
- [7] Sano, A.; Ishihara, M.; Yoshihara, J.; Sumino, N.; Nawa, H. Chem Pharm Bull 1995, 43, 683.
- [8] Belicova, A.; Semon, M.; Milata, V.; Liavsky, D.; Ebringer, L. Folia Microbial Prague 1997, 42, 193; Chem Abstr 1997, 127, 63024x.
- [9] Claremon, D. A.; McCauley, J. A.; Liverton, N. H.; Theberge, C. R. US Patent 2002, 214,654; Chem Abstr 2002, 136, 69819.
- [10] Roma, G.; Braccio, M. D.; Leoncini, G.; Aprile, B. Farmaco 1993, 48, 1225; Roma, G.; Cinone, N.; Braccio, M. D.; Grossi, G.; Leoncini, G.; Singnorello, M. G.; Carotti, A. Bioorg Med Chem 2000, 8, 751; Roma, G.; Cinone, N.; Braccio, M. D.; Grossi, G.; Leoncini, G.; Singnorello, M. G.; Carotti, A. Bioorg Med Chem 2001, 9, 55.
- [11] Lappin, G. R.; Petersen, Q. R.; Wheeler, C. E. J Org Chem 1950, 15, 377.
- [12] Shur, M.; Israeltam, S. S. J Org Chem 1968, 33, 3015.

- [13] Mohamed, E. A.; Abdel-Rahman, R. M.; El-Gendy, Z.; Ismail, M. M. *An Quim Spain* 1993, 89, 246.
- [14] Fiksdahl, A.; Plug, C.; Wentrup, C. *J Chem Soc, Perkin Trans 2* 2000, 1841.
- [15] Halpern, M.; Crick, D. *PTC Communications: Top 10 Opportunities to Improve Process Performance and Profit Using Phase Transfer Catalysis* 2002, Issue 16, p. 8; <http://www.ptcorganics.com>.
- [16] Makosza, M. *Pure Appl Chem* 2000, 72, 1399.
- [17] Silverstein, R. M.; Bassler, C. G.; Morrill, T. C. *Spectrometric Identification of Organic Compounds*, John Wiley & Sons, New York, 3rd ed, 1974, p107.
- [18] Wang, J.-X.; Zhang, Y.; Huang, D.; Hu, Y. *J Chem Research (S)* 1998, 216-217.
- [19] Ferrarini, P. L.; Mori, C.; Badawneh, M.; Calderone, V.; Greco, R.; Manera, C.; Martinelli, A.; Nieri, P.; Sacomanni, G. *Eur J Med Chem* 2000, 35, 815-826.
- [20] Plug, C.; Frank, W.; Wentrup, C. *J Chem Soc, Perkin Trans 2* 1999, 1087.
- [21] Mohamed, E. A.; Ismail, M. M.; Gabr, Y.; Abass, M. *J Serb Chem Soc* 1993, 58, 737-743.
- [22] Mohamed, E. A.; Gabr, Y.; Ismail, M. M.; Abass, M. *An Quim Spain* 1995, 91, 579.
- [23] Laschober, R.; Stadlbauer, W. *Liebigs Ann Chem* 1990, 1083.